Please select the option that best describes you:
How are you counseling HR-proficient ovarian cancer patients about front line PARP inhibitor maintenance?
Given recent approval of niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy
Answer from: Medical Oncologist at Academic Institution
I think this is a tough decision, but I recommend observation for patients with HR proficient disease. In brief, I don't find a PFS advantage, without a proven OS advantage, enough to justify this long-term, expensive, and not non-toxic treatment.For BRCA carriers the answer is easier—with SOL...
Sign in or Register to read more
Answer from: at Community Practice
It’s truly exciting to have new FDA approvals in ovarian cancer. Both the PRIMA trial (González-Martín et al, NEJM 2019) and the PAOLO trial (Ray-Coquard et al NEJM 2019) have led to recent approvals for front-line maintenance therapies. When comparing data for the current front-...
Comments
Medical Oncologist at Northwest Medical Specialties PLLC
Thank you for the explanation. What is the PFS for...
Thank you for the explanation. What is the PFS for...
at Baptist Medical Group
I agree. What is the PFS for BRCA and HRD negative...
I agree. What is the PFS for BRCA and HRD negative...